Yep, would imagine people taking positions. It's less than a month away from Phase 2 results. If it's a success, it's one pivotal registration trial(and PK study) away from coming to market in the US and EU.
If you assume as Fifty One Capital have done; that Presendin will take a 40% share of the Total Addressable Market of $1.6B. Then peak sales are $640 million. Attach a 3-4 multiplier in terms of valuation, and you're left with a possible transaction value of $2B+ for the IIH product alone.
Lots of assumptions in the model, but at a $60 million market cap, it's becoming a very attractive proposition for long term investors.
